Incannex Healthcare Plummets 61.64% in Trading Volume Ranking 380th Despite Patent Milestone

On May 15, 2025, Incannex Healthcare (IXHL) experienced a significant drop of 61.64%, with a trading volume of 2.62 billion, marking a 71.91% decrease from the previous day. This placed Incannex at the 380th position in the daily stock market rankings.

Incannex Healthcare Limited, a biopharmaceutical company, has announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application related to the use of cannabidiol (CBD) in the treatment of autism spectrum disorder (ASD). This development is a significant milestone for the company, as it strengthens its intellectual property portfolio and positions it as a leader in the field of cannabinoid-based therapies.

The company's CEO, Dr. Mark B. Legg, expressed his excitement about the news, stating that the allowance of this patent is a testament to the innovative work being done at Incannex. He also highlighted the potential of CBD as a therapeutic option for individuals with ASD, noting that the company is committed to advancing research in this area.

Incannex's stock price has been volatile in recent months, reflecting the broader market's uncertainty about the future of the cannabis industry. However, this latest development could provide a boost to investor confidence, as it demonstrates the company's ability to innovate and secure valuable intellectual property.